Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Nature Medicine
|
July 4, 2018
Author Correction: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Carsten Krieg, Malgorzata Nowicka, Silvia Guglietta, et al.
Nature Medicine
|
January 9, 2018
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Carsten Krieg, Malgorzata Nowicka, Silvia Guglietta, et al.
Cancer Chemotherapy and Pharmacology
|
February 2, 2024
UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure
Vikram Malhi, Malgorzata Nowicka, Ya-Chi Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2025
Clinical Context Shapes the Relationship Between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Kalpit Shah, Matthew H Secrest, Wei Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2022
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial
Rafal Dziadziuszko, Solange Peters, Tony Mok, et al.
Cancer
|
January 30, 2024
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer
David Mutch, Athina Voulgari, Xian Marissa Chen, et al.
European Urology
|
January 30, 2025
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial
Johann S de Bono, Meng He, Zhen Shi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 24, 2019
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
D Ross Camidge, Rafal Dziadziuszko, Solange Peters, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 2, 2023
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
Carsten Denkert, Chiara Lambertini, Peter A Fasching, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2021
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Zhen Shi, Julia Wulfkuhle, Malgorzata Nowicka, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Nature Medicine
|
July 4, 2018
Author Correction: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Carsten Krieg, Malgorzata Nowicka, Silvia Guglietta, et al.
Nature Medicine
|
January 9, 2018
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Carsten Krieg, Malgorzata Nowicka, Silvia Guglietta, et al.
Cancer Chemotherapy and Pharmacology
|
February 2, 2024
UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure
Vikram Malhi, Malgorzata Nowicka, Ya-Chi Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2025
Clinical Context Shapes the Relationship Between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
Kalpit Shah, Matthew H Secrest, Wei Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2022
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial
Rafal Dziadziuszko, Solange Peters, Tony Mok, et al.
Cancer
|
January 30, 2024
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer
David Mutch, Athina Voulgari, Xian Marissa Chen, et al.
European Urology
|
January 30, 2025
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial
Johann S de Bono, Meng He, Zhen Shi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 24, 2019
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
D Ross Camidge, Rafal Dziadziuszko, Solange Peters, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 2, 2023
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
Carsten Denkert, Chiara Lambertini, Peter A Fasching, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2021
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Zhen Shi, Julia Wulfkuhle, Malgorzata Nowicka, et al.
Page
of 3